Mechanism of action<unk>  is an IgG1k monoclonal antibody directed against CD38. CD38 is overexpressed in multiple myeloma cells.<unk>  binds to a different CD38 epitope amino-acid sequence than does the anti-CD38 monoclonal antibody isatuximab.<unk>  binds to CD38, causing cells to apoptose via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, inhibition of mitochondrial transfer or antibody-dependent cellular phagocytosis. These effects are dependent upon fragment crystallizable region immune effector mechanisms. Antibody-dependent cellular cytotoxicity is by means of natural killer cells. Unlike isatuximab which causes apoptosis directly,<unk>  only induces apoptosis indirectly. Multiple myeloma cells with higher levels of CD38 show greater<unk> -mediated cell lysis than cells with low CD38 expression. CD38 enzyme results in the formation of the immunosuppressive substance adenosine, so eliminating CD38-containing cells increases the ability of the immune system to eliminate cancer.
Daratumumab
Lanadelumab
Ofatumumab
Alirocumab
Tralokinumab
Olaratumab
Evinacumab
Ustekinumab